CAMBRIDGE, Mass., April 26,
2022 /PRNewswire/ -- Blueprint Medicines
Corporation (NASDAQ: BPMC) today announced that it will host a live
conference call and webcast at 8:30 a.m. ET
on Tuesday, May 3, 2022 to report its first quarter 2022
financial results and provide a corporate update.
To access the live conference call, please dial 844-200-6205
(domestic) or 929-526-1599 (international), and refer to conference
ID 694684. A webcast of the call will also be available under
"Events and Presentations" in the Investors & Media section of
the Blueprint Medicines website
at http://ir.blueprintmedicines.com/. The archived webcast
will be available on Blueprint Medicines' website
approximately two hours after the conference call and will be
available for 30 days following the call.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company
that invents life-changing therapies for people with cancer and
blood disorders. Applying an approach that is both precise and
agile, we create medicines that selectively target genetic drivers,
with the goal of staying one step ahead across stages of disease.
Since 2011, we have leveraged our research platform, including
expertise in molecular targeting and world-class drug design
capabilities, to rapidly and reproducibly translate science into a
broad pipeline of precision therapies. Today, we are delivering
approved medicines directly to patients in the United
States and Europe, and we are globally advancing multiple
programs for systemic mastocytosis, lung cancer and other
genomically defined cancers, and cancer immunotherapy. For more
information, visit www.BlueprintMedicines.com and follow
us on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-first-quarter-2022-financial-results-on-tuesday-may-3-2022-301532566.html
SOURCE Blueprint Medicines Corporation